Key points are not available for this paper at this time.
Atezolizumab plus nab-paclitaxel prolonged progression-free survival among patients with metastatic triple-negative breast cancer in both the intention-to-treat population and the PD-L1-positive subgroup. Adverse events were consistent with the known safety profiles of each agent. (Funded by F. Hoffmann-La Roche/Genentech; IMpassion130 ClinicalTrials.gov number, NCT02425891 .).
Building similarity graph...
Analyzing shared references across papers
Loading...
Schmid et al. (Sat,) studied this question.
www.synapsesocial.com/papers/6941d1c8a0e04400c528bde5 — DOI: https://doi.org/10.1056/nejmoa1809615
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
Peter Schmid
Sylvia Adams
Hope S. Rugo
New England Journal of Medicine
University of California, San Francisco
New York University
Dana-Farber Cancer Institute
Building similarity graph...
Analyzing shared references across papers
Loading...